Contineum Therapeutics (CTNM) EPS (Weighted Average and Diluted) (2023 - 2026)

Contineum Therapeutics' EPS (Weighted Average and Diluted) history runs 4 years deep, the most recent figure standing at -$0.39 for Q1 2026.

• In Q1 2026, EPS (Weighted Average and Diluted) rose 37.1% year-over-year to -$0.39; the TTM figure through Mar 2026 stood at -$1.98 (changed 0.0% YoY), while the FY2025 annual figure was -$2.17, changed 0.46% from the prior year.
• EPS (Weighted Average and Diluted) was -$0.39 for Q1 2026 at Contineum Therapeutics, up from -$0.55 in the prior quarter.
• In the past five years, EPS (Weighted Average and Diluted) ranged from a high of $0.84 in Q2 2023 to a low of -$2.69 in Q3 2023.
• Historically, EPS (Weighted Average and Diluted) has averaged -$0.57 across 4 years, with a median of -$0.4 in 2024.
• Biggest YoY gain for EPS (Weighted Average and Diluted) was 85.13% in 2024; the steepest drop was 146.43% in 2024.
• A 4-year view of EPS (Weighted Average and Diluted) shows it stood at -$0.35 in 2023, then sank by 62.86% to -$0.57 in 2024, then climbed by 4.34% to -$0.55 in 2025, then gained by 28.48% to -$0.39 in 2026.
• The last three EPS (Weighted Average and Diluted) figures came in at -$0.39 (Q1 2026), -$0.55 (Q4 2025), and -$0.62 (Q1 2025), per Business Quant data.